Scarica l'app Stockscreener
1.9615
3.81%
-0.0385
Precedente Chiudi:
$2.00
Aprire:
$2.02
Volume 24 ore:
14,597
Relative Volume:
0.05
Capitalizzazione di mercato:
$118.72M
Reddito:
-
Utile/perdita netta:
$-64.86M
Rapporto P/E:
-1.7513
EPS:
-1.12
Flusso di cassa netto:
$-55.66M
1 W Prestazione:
+2.33%
1M Prestazione:
-5.23%
6M Prestazione:
+79.79%
1 anno Prestazione:
-9.25%
Intervallo 1D:
$1.9363
$2.02
Intervallo di 1 settimana:
$1.75
$2.02
Portata 52W:
$0.8551
$2.46
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Nome
Acumen Pharmaceuticals Inc
Settore
Industria
Telefono
617-344-4190
Indirizzo
1210-1220 WASHINGTON STREET, NEWTON
Confronta ABOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.96 | 119.94M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.07 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
732.59 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.05 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
913.29 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.75 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-07-26 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-20 | Ripresa | BofA Securities | Buy |
| 2023-05-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Iniziato | BTIG Research | Buy |
| 2022-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-07-26 | Iniziato | BofA Securities | Neutral |
| 2021-07-26 | Iniziato | Credit Suisse | Outperform |
| 2021-07-26 | Iniziato | Stifel | Buy |
| 2021-07-26 | Iniziato | UBS | Buy |
Mostra tutto
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
Is Acumen Pharmaceuticals Inc. stock a dividend growth opportunityJuly 2025 Fed Impact & Community Consensus Picks - Newser
Can Acumen Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Acumen presents new research on Alzheimer’s treatment delivery By Investing.com - Investing.com Canada
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga
Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference - Yahoo
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
What analysts say about Acumen Pharmaceuticals Inc stockStock Liquidity Analysis & Invest Like A Pro - earlytimes.in
Acumen Pharmaceuticals highlights enhanced brain delivery technology for oligomer-selective antibodies - marketscreener.com
Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Wall Street analysts’ outlook for Acumen Pharmaceuticals Inc (ABOS) - Setenews
Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - moha.gov.vn
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts - Defense World
Is Acumen Pharmaceuticals Inc a good long term investmentTrade Execution Strategies & Big Profit Small Investment - earlytimes.in
Published on: 2025-11-21 08:02:34 - newser.com
Will Acumen Pharmaceuticals Inc. stock go up soonTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Why Acumen Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - newser.com
Using data models to predict Acumen Pharmaceuticals Inc. stock movementQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
How risky is Acumen Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Is Acumen Pharmaceuticals Inc. stock dividend yield sustainableQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Can Acumen Pharmaceuticals Inc. rally from current levelsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Acumen Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Acumen Pharmaceuticals Inc. stockJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Is Acumen Pharmaceuticals Inc. stock attractive for passive investorsQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq
ABOS: B of A Securities Lowers Price Target But Maintains Buy Ra - GuruFocus
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - The Manila Times
SR Bancorp (NASDAQ: SRBK) announces $0.05 dividend payable Oct. 15 - Stock Titan
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug By Investing.com - Investing.com Canada
How to forecast Acumen Pharmaceuticals Inc. trends using time seriesJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
Acumen stock maintains Buy rating at Stifel ahead of late-2026 readout - Investing.com UK
Acumen Pharmaceuticals Reports Q3 2025 Financial Results - MSN
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease - The Manila Times
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug - Investing.com India
Acumen Pharmaceuticals (NASDAQ: ABOS) doses first patient in Phase 2, 52-week OLE - Stock Titan
Will a bounce in Acumen Pharmaceuticals Inc. offer an exitJobs Report & Expert Curated Trade Setups - newser.com
Tools to monitor Acumen Pharmaceuticals Inc. recovery probabilityMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Acumen Pharmaceuticals Inc Azioni (ABOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acumen Pharmaceuticals Inc Azioni (ABOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
0.46%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):